Table 4.

Immune checkpoint inhibitors for pancreatic cancer.

	Ipilimumab [33]	Tremelimumab [34]	Durvalumab [35]	Durvalumab + Tremelimumab [35]
N	27	20	33	32
Response rate	0	0	0	3.1%
Disease control rate		0	6.1%	9.4%
Median PFS		1.8 months	1.5 months	1.5 months
Median OS		4 months	3.6 months	3.1 months

PFS, Progression-free survival; OS, overall survival.